Quarterly report · Q2
2269.TEDINET S100PI81
Period2022-04-01 → 2022-09-30
Filed2022-11-09
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥517.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥1.01T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥500.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥43.2bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥50.3bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥43.9bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥94.0bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥51.8bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥48.3bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥55.2bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥33.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥87.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥36.6bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥34.9bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥40.0bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥1.18T | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥1.12T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.14T | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥426.8bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥404.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥757.0bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥713.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥695.7bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥92.1bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥67.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥88.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.9bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥80.9bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥39.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥25.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥127.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥61.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥26.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥27.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥35.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥20.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥77.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥14.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥237.04 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.31 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥607.24 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥252.54 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥166.44 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 60.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.3% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.4% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥292m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥292m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥786m |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥420.6bn |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥420.4bn |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥278m |
| jpcrp040300-q2r_E21902-000Foodreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥29.3bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥97.2bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥97.2bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥13m |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥14.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥517.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥517.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥292m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥44.0bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥468m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥468m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥534m |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥409.1bn |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥408.8bn |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥254m |
| jpcrp040300-q2r_E21902-000Foodreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥39.6bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥92.1bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥91.9bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥214m |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥11.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥501.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥500.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥468m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥50.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 561
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |